Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03871686
Other study ID # 2019-0006
Secondary ID A177800EDUC/REHA
Status Completed
Phase N/A
First received
Last updated
Start date February 13, 2019
Est. completion date May 19, 2019

Study information

Verified date February 2020
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of an Internet-based, behavioral activation intervention to promote well-being in a young adult survivors of childhood brain tumor.


Description:

Participants will be recruited through the Children's Brain Tumor Foundation who will share the study announcement with their young adult members and social media. Eligible participants will complete a baseline battery survey via Qualtrics. The investigators will recruit 120 participants. The survey will take approximately 30 minutes to complete. Participants will be randomly assigned to an experimental group or control group. The experimental group will take an Internet-based behavioral activation intervention. The intervention has four modules and will be administered via Qualtrics. A link to each module will be sent to the participants via e-mail. Participants will have one week to complete each module. Once a participant completes a module, the next module link will be sent after 3 days. A reminder will be sent at 7 days and 10 days until the module is complete. Each module will take approximately 30 minutes to complete. The experimental group may continue to receive services as usual from the Children's Brain Tumor Foundation. The control group will continue to receive services as usual from the Children's Brain Tumor Foundation. The control group will have an opportunity to take the intervention once data collection is complete. Both groups will be asked to complete a battery of surveys at the end of the intervention and intermittently over a 3-month period.


Recruitment information / eligibility

Status Completed
Enrollment 139
Est. completion date May 19, 2019
Est. primary completion date May 19, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria:

- History of childhood brain tumor

- Ages of 18 and 30 years.

- Have regular access to the Internet

- Provide an e-mail address

Exclusion Criteria:

- Those that do not meet the inclusion criteria.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Brief Internet-based Behavioral Activation Intervention
A brief Internet-based behavioral activation intervention consisting of 4 sessions.

Locations

Country Name City State
United States Children's Brain Tumor Foundation New York New York

Sponsors (1)

Lead Sponsor Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline PERMA-Profiler score at 2 weeks and 3 months The PERMA-Profiler is a general measure of well-being (Butler & Kern, 2016). The PERMA-Profiler measures Seligman's (2011) five pillars of well-being: positive emotion, engagement, relationships, meaning, and accomplishment. The measure consists of 23 items, including three items for each domain. The health, negative emotion, loneliness, and overall happiness items act as filler questions and provide more information. Items are rated on an 11-point Likert scale ranging from 0 (never) to 10 (always), or 0 (not at all) to 10 (completely). Scores are calculated as the average of the items comprising each factor. Butler and Kern (2016) suggested that the multidimensional structure be retained, rather than condensing responses; however, a single well-being score may provide a global indication of well-being. Therefore, for the current study, total scores for each subscale will be calculated as well as the total scores. Change from baseline total score will be assessed. At baseline; 2 weeks and 3 months after completing the intervention.
Secondary Change from baseline World Health Organization-Disability Assessment Schedule 2.0 score at 2 weeks and 3 months Measures overall health, functioning, and disability. Total scores range from 0 to 24. Scores are summed with higher scores indicating greater functional disability severity. At baseline; 2 weeks and 3 months after completing the intervention.
Secondary Change from baseline Life Satisfaction Scale (LiSat-9) score at 2 weeks and 3 months To measure satisfaction with life, the Life Satisfaction Questionnaire (LiSat-9; Fugl-Meyer et al., 1991) will be included. The LiSat-9 has 9 items; including one general life satisfaction item. There 8 are domain-specific items for vocational situation, financial situation, leisure, contact friends, sexual life, activities of daily living, family life, and partnership relationship. Items are rated on an Likert scale ranging from 1 (very dissatisfying) to 6 (very satisfying). Scoring consists of calculating the mean score. Higher scores indicate greater satisfaction with life. At baseline; 2 weeks and 3 months after completing the intervention.
Secondary Change in baseline Perceived Stress Scale score at 2 weeks and 3 months To measure perceived stress, the Perceived Stress Scale (PSS; Cohen & Williamson, 1988) will be used. The PSS is a widely used 10-item scale in which respondents rate how stressful (unpredictable, uncontrollable, and overloaded) they perceive their lives to have been within the past month. Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). Scoring consists of calculating the mean score. Higher scores indicate greater perceived stress. At baseline; 2 weeks and 3 months after completing the intervention.
Secondary Change in baseline Acceptance and Action Questionnaire (AAQ-II) score at 2 weeks and 3 months The Acceptance and Action Questionnaire (AAQ-II) (Bond et al., 2011) consists of seven items to be answered on a scale of 1 (never true) to 7 (always true). The AAQ-II measures participants' willingness to live in accordance with their values, in contact with negative private events, and acceptance of these events. A higher total score indicates a higher level of psychological flexibility, that is higher acceptance and less experiential avoidance. Total mean score will be calculated. At baseline; 2 weeks and 3 months after completing the intervention.
Secondary Change in baseline Behavioral Activation for Depression Scale (BADS-9) score at 2 weeks and 3 months The Behavioral Activation for Depression Scale- Short Form (BADS-9) is a 9-item scale with scores ranging from 0 to 54, with high scores representing higher activation. Total mean scores will be calculated. At baseline; 2 weeks and 3 months after completing the intervention.
Secondary Change in baseline Cognitive-Behavioral Social Self-Efficacy Scale score at 2 weeks and 3 months The Cognitive-Behavioral Social Self-Efficacy Scale is an 18-item measure of perceived social self-efficacy. Item scores range from 1 (not confident at all) to 5 (very confident. Total scores range from 18 to 90, with higher scores representing greater perceived social self-efficacy. Total mean scores will be calculated. At baseline; 2 weeks and 3 months after completing the intervention.
Secondary Change in baseline Vocational Outcomes Expectancy Scale score at 2 weeks and 3 months The Vocational Outcome Expectancy Scale (VOES) measures outcome expectancy related to employment. It is an 11-item scale with item scores ranging from 1 (strongly disagree) to 5 (strongly agree). Total scores range from 11 to 55, with higher scores representing a greater expectation of attaining positive employment outcomes (i.e., obtaining or retaining employment). Total mean scores will be calculated. At baseline; 2 weeks and 3 months after completing the intervention.
Secondary Change in baseline Perceived Barrier Scale score at 2 weeks and 3 months The Perceived Career Barriers measure was developed to identify barriers to career development and employment of young adult survivors of pediatric brain tumors (Strauser et al., 2018). The 12-item measure uses an 11-point Likert Scale (0-10) with 0 being (not a barrier) and 10 being a (major barrier). A midpoint label of (somewhat of a barrier) is utilized. Total scores range from 0 to 110, with higher scores indicating greater perceived career barriers. At baseline; 2 weeks and 3 months after completing the intervention.
Secondary Change in baseline General Self-Efficacy Scale score at 2 weeks and 3 months The General Self-Efficacy Scale (GSES) is a measure of general self-efficacy. It is a 10-item measure with item scores ranging from 1 (not true at all) to 4 (exactly true). Total scores range between 10 and 40, with a higher score indicating more self-efficacy. At baseline; 2 weeks and 3 months after completing the intervention.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1
Recruiting NCT04738162 - Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors Phase 2
Not yet recruiting NCT06093165 - RE-irradiation of Diffuse MIdline Glioma paTients N/A
Recruiting NCT05298995 - GD2-CAR T Cells for Pediatric Brain Tumours Phase 1
Recruiting NCT05709522 - Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
Recruiting NCT04722237 - Acceptance and Commitment Therapy for Neuro-Oncology Wellbeing N/A
Recruiting NCT06309251 - Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Recruiting NCT04670016 - HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
Active, not recruiting NCT03086421 - Social Emotional Development in Young Children With Cancer
Active, not recruiting NCT03361033 - Components of Social Functioning in Survivors of Pediatric Brain Tumors
Active, not recruiting NCT04525014 - RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors Phase 1
Recruiting NCT05672043 - Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
Recruiting NCT05553899 - Utility of PET-MRI in Surveillance of Paediatric Brain Tumours N/A
Withdrawn NCT04019470 - Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors
Active, not recruiting NCT04023669 - Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors Phase 1
Suspended NCT05169944 - Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors Phase 1